Artículo de revisión

Published on 20 de octubre de 2025 | http://doi.org/10.5867/medwave.2025.09.3026

Available evidence on integrating COVID-19 into sentinel surveillance systems: A scoping review

Back to article
Comparison of clinical findings of COVID-19.
Location and yearStudy designKey featuresMedian prevalence of symptoms
United Kingdom, 2022Systematic review (14 studies)Addresses definitions ILI, ARI, SARI. China (69.7%), Europe (23.9%), and the United States (9.0%).General symptoms: fever (73%, IQR = 58.3 to 78.7), cough (51.8%, IQR = 45 to 59.7), loss of taste or smell (45.1%, IQR = 28.9 to 54.0), hypoxemia (33%), expectoration (23.9%, IQR = 23.3 to 25.5).
Adults: loss of taste/olfactory (30.5%, IQR = 15.7 to 45.2), hypoxemia (33%).
Children: fever (58.3%, IQR = 56.6–59.9), cough (43%, IQR = 42 to 44), headache (34.3%, IQR = 18 to 50.7), nasal congestion (20%), muscle ache (19.6%, IQR = 11.8 to 27.3).
California, USA, 2022Cross-sectional studyCommunity transmission monitoring (n = 1696)Cough (55.6%), headache (48.6%), muscle pain (44.5%), sore throat (37.4%), and fever (35.3%).
Kenya, 2022Cross-sectional studySurveillance of SARS-CoV-2 and other pathogens (n = 177)Rhinorrhea (68.4%), fatigue (54.1%), myalgia (53.7%), fever (52%), anosmia (24.9%), diarrhea (3.9%).

ILI, influenza-like illness. SARI, Severe Acute Respiratory Infection. ARI, acute respiratory infection. IQR, interquartile range.

Critical appraisal data from the included evidence sources are available at: https://doi.org/10.6084/m9.figshare.27273600.v.

Source: Prepared by the authors of this study.